Mycophenolate mofetil HCl | CAS # 116680-01-4 | IMPDH inhibitor

MedKoo Cat#: 412553 | Name: Mycophenolate mofetil HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). It is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants.

Chemical Structure

Mycophenolate mofetil HCl

CAS#116680-01-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 412553

Name: Mycophenolate mofetil HCl

CAS#: 116680-01-4 (HCl)

Chemical Formula: C23H32ClNO7

Exact Mass: 0.0000

Molecular Weight: 469.96

Elemental Analysis: C, 58.78; H, 6.86; Cl, 7.54; N, 2.98; O, 23.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

128794-94-5 (free acid) 116680-01-4 (HCl)

Synonym

Mycophenolate mofetil hydrochloride; RS61443-190; RS-61443-190; RS 61443-190

IUPAC/Chemical Name

4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, hydrochloride, (4E)-

InChi Key

OWLCGJBUTJXNOF-HDNKIUSMSA-N

InChi Code

InChI=1S/C23H31NO7.ClH/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3;/h4,26H,5-14H2,1-3H3;1H/b15-4+;

SMILES Code

O=C(OCCN1CCOCC1)CC/C(C)=C/CC2=C(O)C3=C(COC3=O)C(C)=C2OC.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 469.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Riedl Khursigara M, Chung E, Tjon J, Noone D, Chami R, Licht C, Teoh CW. Utilizing therapeutic drug monitoring to optimize therapy with eculizumab and mycophenolate mofetil in a child with C3 glomerulonephritis. Pediatr Nephrol. 2023 Mar 8. doi: 10.1007/s00467-023-05927-9. Epub ahead of print. PMID: 36884075. 2: Drevland OM, Robertsen I, Theie Gustavsen M, Kveim HK, Herberg Hovd M, Midtvedt K, Åsberg A. Impact of Fasting Status and Circadian Variation on the Pharmacokinetics of Mycophenolate Mofetil and the Glucuronide Metabolite in Renal Transplant Recipients. Transplant Direct. 2023 Feb 8;9(3):e1448. doi: 10.1097/TXD.0000000000001448. PMID: 36875939; PMCID: PMC9977486. 3: Trevisonno M, Hall A, Rosengarten S, Ginzler EM. Mycophenolate Mofetil for Systemic Lupus Erythematosus: Our 20-Year Experience. Cureus. 2023 Jan 30;15(1):e34413. doi: 10.7759/cureus.34413. PMID: 36874710; PMCID: PMC9977607. 4: Wang B, Xi W, Li H. Mycophenolate mofetil-associated collagenous ileitis in a kidney transplant recipient: A case report. Clin Nephrol. 2023 Mar 5. doi: 10.5414/CN111055. Epub ahead of print. PMID: 36871227. 5: Kadokawa Y, Inoue S, Tatsumi A, Uchida M, Fujita K, Takagi M, Inoue T, Ohe S, Nakai Y, Otsuka T, Abe Y, Nakabori T, Isei T, Kumagai T, Nishimura K, Ohkawa K. Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective study. JGH Open. 2023 Feb 13;7(2):87-97. doi: 10.1002/jgh3.12868. PMID: 36852148; PMCID: PMC9958334. 6: Labriffe M, Micallef L, Woillard JB, Monchaud C, Saint-Marcoux F, Debord J, Marquet P. Mycophenolate Mofetil Dose Adjustment in Pediatric Kidney Transplant Recipients. Ther Drug Monit. 2023 Feb 22. doi: 10.1097/FTD.0000000000001087. Epub ahead of print. PMID: 36823705. 7: Park JI, Song GW, Ryu JH, Choi ST, Choi NG, Jung BH, Chu CW, Kim KK, Jung DH, Ha TY, Moon DB, Yang K, Shin MH, Chung YK, Hwang S, Yoon YI, Lee SG. A Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Tacrolimus and Corticosteroids in Combination With or Without Mycophenolate Mofetil in Liver Transplantation Recipients Infected With Hepatitis B Virus. Transplant Proc. 2023 Feb 21:S0041-1345(23)00005-2. doi: 10.1016/j.transproceed.2023.01.013. Epub ahead of print. PMID: 36822884. 8: Tian JX, Miao WJ, Yan HH, Wang XD, Liao YX, Li S, Jiang EL, Zhang P. Impact of carbapenem antibiotics on mycophenolate mofetil in hematopoietic stem cell transplant patients with interruption of the enterohepatic recycling: a retrospective study. Ann Transl Med. 2023 Jan 31;11(2):82. doi: 10.21037/atm-22-6341. PMID: 36819591; PMCID: PMC9929831. 9: Yun T, Son M, Koo Y, Chae Y, Lee D, Kim H, Yang MP, Kang BT. Erratum to Topics in Companion Animal Medicine, 52C (2022)100755. Top Companion Anim Med. 2023 Feb 16:100761. doi: 10.1016/j.tcam.2023.100761. Epub ahead of print. Erratum for: Top Companion Anim Med. 2023 Jan-Feb;52:100755. PMID: 36803420. 10: Fontana F, Delsante M, Vicari M, Pala C, Alfano G, Giovanella S, Ligabue G, Leonelli M, Manenti L, Rossi GM, Magistroni R, Fiaccadori E, Donati G. Mycophenolate mofetil plus steroids compared to steroids alone in IgA nephropathy: a retrospective study. J Nephrol. 2023 Mar;36(2):297-300. doi: 10.1007/s40620-023-01578-z. Epub 2023 Feb 15. PMID: 36790645. 11: Chen Y, Li R, Luo X, Wu T, Li J, Liu Z, Peng Y, Lu H, Peng L, Zhou J, Zhao Y, Zeng X, Fei Y, Zhang W. Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study. Clin Rheumatol. 2023 Feb 13. doi: 10.1007/s10067-023-06528-5. Epub ahead of print. PMID: 36781683. 12: Kridin K, Mruwat N, Amber KT, Ludwig RJ. Risk of infections in patients with pemphigus treated with rituximab versus azathioprine or mycophenolate mofetil: A large-scale global cohort study. Br J Dermatol. 2023 Jan 10:ljac118. doi: 10.1093/bjd/ljac118. Epub ahead of print. PMID: 36763798. 13: Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, Nie S, Liang M, Wang G, Jia N; MAIN Trial Investigators. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial. JAMA Netw Open. 2023 Feb 1;6(2):e2254054. doi: 10.1001/jamanetworkopen.2022.54054. PMID: 36745456. 14: Sura AA, Sun Y, Reddy AK, Rathinam SR, Gonzales JA, Thundikandy R, Vedhanayaki R, Kanakath A, Murugan B, Doan TA, Lim LL, Suhler EB, Al-Dhibi HA, Acharya NR; FAST Research Group. Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial. Ocul Immunol Inflamm. 2023 Jan 26:1-6. doi: 10.1080/09273948.2023.2165949. Epub ahead of print. PMID: 36701644. 15: Han Q, Han J, Wang W, Gao J, Qiao Y, Jia J, Zhang K, Zheng Z, Zhu P. Case report: Kimura's disease with minimal degenerative glomerulopathy without eosinophil infiltration responds to mycophenolate mofetil treatment. Front Med (Lausanne). 2023 Jan 9;9:1069553. doi: 10.3389/fmed.2022.1069553. PMID: 36698834; PMCID: PMC9868591. 16: Rhu J, Kim JM, Choi GS, Joh JW. Pre-transplant mycophenolate mofetil may be associated with reduced intrahepatic cholangiopathy in ABO-incompatible liver transplantation. Liver Transpl. 2023 Jan 26. doi: 10.1097/LVT.0000000000000070. Epub ahead of print. PMID: 36695301. 17: Reinisch CB, Azam AM, Cheung AY, Govil A, Holland EJ. Perioperative management of high-risk corneal transplantation using basiliximab and mycophenolate mofetil. Can J Ophthalmol. 2023 Jan 15:S0008-4182(22)00394-5. doi: 10.1016/j.jcjo.2022.12.009. Epub ahead of print. PMID: 36649916. 18: Mizaki T, Nobata H, Banno S, Yamaguchi M, Kinashi H, Iwagaitsu S, Ishimoto T, Kuru Y, Ohnishi M, Sako KI, Ito Y. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis. J Pharm Health Care Sci. 2023 Jan 9;9(1):1. doi: 10.1186/s40780-022-00271-w. PMID: 36624529; PMCID: PMC9830922. 19: Lee YH, Song GG. Efficacy and safety of tacrolimus versus mycophenolate mofetil as induction treatment and low-dose tacrolimus as treatment for lupus nephritis: a meta-analysis. Z Rheumatol. 2023 Jan 6. English. doi: 10.1007/s00393-022-01313-2. Epub ahead of print. PMID: 36607421. 20: Yun T, Koo Y, Chae Y, Lee D, Kim H, Yang MP, Kang BT. Successful Treatment With Prednisolone and Mycophenolate Mofetil in a Dog With Recurrent Erythema Multiforme Minor. Top Companion Anim Med. 2023 Jan-Feb;52:100755. doi: 10.1016/j.tcam.2022.100755. Epub 2022 Dec 28. Erratum in: Top Companion Anim Med. 2023 Feb 16;:100761. PMID: 36586578.